Solventum (SOLV) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Leadership vision and organizational transformation

• Leadership team with prior successful spin-off experience is focused on value creation and portfolio optimization.

• Early months post-separation have shown strong business continuity and high employee engagement.

• Attrition rates are lower than expected, with rapid hiring of capable leaders at multiple levels.

• Cultural shift toward faster decision-making and accountability is underway, with some expected churn.

• The company is leveraging strong intellectual property and brand recognition as foundational assets.

Business segment performance and strategy

• MedSurg, representing nearly 60% of revenue, is underperforming but has a strong base and leadership changes to drive focus.

• R&D and commercialization processes are being realigned for better innovation cadence and market fit.

• Dental segment is profitable but slow-growing; future investment hinges on success in the aesthetics market.

• HIS (Health Information Systems) is a solid, sticky business with high market share in revenue cycle management; investment in clinician productivity solutions is under evaluation.

• Purification and Filtration is a smaller but attractive business, with bioprocessing as a high-margin, high-potential area.

Financial outlook and investment approach

• Q3 faces tougher comps due to prior pricing benefits and backorder recovery; H2 expected to be flat to slightly positive.

• Full-year guidance raised to 0–1% growth, with Q4 comps expected to ease.

• Focus is on balancing investment in growth with operational efficiencies, with a structural optimization project underway.

• Long-term strategy aims to achieve mid-single-digit market growth rates by investing in segment-specific growth levers.

• 2025 guidance and long-range plan will reflect the balance between investment and efficiency gains.